Eli Lilly and Company
For nearly 150 years, we’ve made significant and game-changing progress on our mission to make life better for people around the world. We’ve remained headquartered in Indianapolis, Indiana, since our founding on May 10, 1876, but our employees now work in countries around the world.
And thanks to the dedication of our diverse global team, we’ve been able to answer the call for new medicines to help solve some of the world’s most significant health challenges
When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
47,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know Team Lilly through our Powered by Purpose series.
NEWS
Convalescent and Therapeutic Antibodies and Older Vaccines Suggest Glimmers of Hope Against COVID-19
The amount of scientific information unearthed about SARS-CoV-2, the virus that causes COVID-19, in only six months is unprecedented. The speed is remarkable, although much of it will still need to be confirmed over time with more careful study. Still, each day presents new data with a glimmer of hope. Here’s a look at some recent findings.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
In an interview, Lilly’s CSO said the third antibody could possibly begin human trials in the new few weeks. But the statement that got everyone more excited was when he indicated one of the antibodies might be available for use by September.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
The two companies were able to get their antibody candidate into the clinic within two months of announcing their collaboration in response to the global pandemic.
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
Tauvid is the first and only approved diagnostic agent for imaging tau neurofibrillary tangles (NFTs) in the brain.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
JOBS
IN THE PRESS